Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2022
Programm
Poster
Personen
Suche
DE
Alle Personen
Richard B. Lipton
Sortiert nach Typ
Datum
Vorsitz
08.12.2022
09:45
–
10:45
Plenary and EHF session
New guidelines: Round table discussion
Strauss 2-3
Invited speaker
08.12.2022
17:45
–
18:05
15 Min.
5 Min.
Invited lecture
The interictal state of headache
Vortrag
08.12.2022
18:55
–
18:56
1 Min.
0 Min.
On Demand
The interictal state of headache
09.12.2022
15:55
–
16:00
3 Min.
2 Min.
ePoster
P143
Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Migraine
Weitere Beteiligungen
09.12.2022
15:30
–
15:35
3 Min.
2 Min.
ePoster
P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:35
–
15:40
3 Min.
2 Min.
ePoster
P103
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Migraine
09.12.2022
15:35
–
15:40
3 Min.
2 Min.
ePoster
P243
Characterizing Neck Pain With Headache in People With and Without Migraine: Results From the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study
Epidemiology
09.12.2022
15:40
–
15:45
3 Min.
2 Min.
ePoster
P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:40
–
15:45
3 Min.
2 Min.
ePoster
P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:45
–
15:50
3 Min.
2 Min.
ePoster
P105
Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials
Migraine
09.12.2022
15:45
–
15:50
3 Min.
2 Min.
ePoster
P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:50
–
15:55
3 Min.
2 Min.
ePoster
P142
Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Migraine
09.12.2022
15:50
–
15:55
3 Min.
2 Min.
ePoster
P124
Characterizing gaps in preventive treatment of migraine: global results from the CaMEO-International study
Migraine
09.12.2022
15:55
–
16:00
3 Min.
2 Min.
ePoster
P143
Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Migraine
09.12.2022
15:55
–
16:00
3 Min.
2 Min.
ePoster
P177
Iprazochrome and codeine – unlikely winners in migraine treatment in Poland. Targeting areas for improvement in migraine treatment (results from
Migraine in Poland
- a nationwide cross-sectional survey)
Data science in research and digital medicine, Migraine
09.12.2022
16:10
–
16:15
3 Min.
2 Min.
ePoster
P110
Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
Migraine
09.12.2022
16:35
–
16:40
3 Min.
2 Min.
ePoster
P153
Prevalence of sinonasal symptoms in migraine without aura (results from
Migraine in Poland -
a nationwide cross-sectional survey)
Migraine
09.12.2022
16:40
–
16:45
3 Min.
2 Min.
ePoster
P117
Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
Migraine
09.12.2022
16:40
–
16:45
3 Min.
2 Min.
ePoster
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:45
–
16:50
3 Min.
2 Min.
ePoster
P118
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: methods and global findings for diagnosis rates and care
Migraine
09.12.2022
16:45
–
16:50
3 Min.
2 Min.
ePoster
P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:50
–
16:55
3 Min.
2 Min.
ePoster
P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:55
–
17:00
3 Min.
2 Min.
ePoster
P120
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
Migraine
v1.19.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz